Effect of TrueTear Corneal Surface Imaging
Effect of TrueTear Use on Anterior Corneal Surface Imaging Quality
Sponsor study identifier
interventional
45
1 country
1
Study Start
August 13, 2018
Actual (reported)Primary Completion
July 8, 2019
Actual (reported)Study Completion
July 8, 2019
Actual (reported)This study will evaluate the utility of TrueTear™ to improve anterior corneal surface imaging quality before cataract surgery, refractive lens exchange, or laser refractive surgery.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 8, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 3, 2018
Actual (reported)August 13, 2018
Actual (reported)August 20, 2018
Actual (reported)July 8, 2019
Actual (reported)July 8, 2019
Actual (reported)August 3, 2020
Actual (reported)Surface Asymmetry Index (SAI) Assessed With Corneal Topography
Surface asymmetry index (SAI) is an index that indicates an average value of the corneal power differences between the points spatially located at 180° from 128 equidistant meridians. A radially symmetrical surface has a value of zero, and this value increases as the degree of asymmetry is greater. Higher values are worse, but there is no set maximum value and no unit of measure.
Change from baseline SAI at 5-10 minutes after using the TrueTear device.
Surface Regularity Index (SRI) Assessed With Corneal Topography
Change from baseline SRI at 5-10 minutes after using the TrueTear device.
Use of TrueTear device to stimulate tear production
Ues of TrueTear neurostimulator
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Price Vision Group
Indianapolis, Indiana, 46260, United States
Francis W Price, Jr., MD
Price Vision Group
45 participants (actual enrollment reported by the registry).
First Submitted
August 3, 2018
First Posted
August 20, 2018
Study Start
August 13, 2018
Actual (reported)Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
Contact the study team to confirm eligibility.
Primary Completion
July 8, 2019
Actual (reported)Study Completion
July 8, 2019
Actual (reported)Last Updated
August 11, 2020
Results First Posted
August 3, 2020
Record last verified: 2020-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: